Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes

Epigenomics

Volumn 6, Issue 4, 2014, Pages 371-374

  Christopeit, Maximilian ^a   Bartholdy, Boris ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AML; DNA cytosine methylation; epigenetics; prognosis

Indexed keywords

DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE METHYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DNA METHYLATION; EPIGENETICS; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; REVIEW; RISK ASSESSMENT; ANIMAL; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84908152057     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.32     Document Type: Review

References (32)

1. Patel JP, Gonen M, Figueroa ME et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366(12), 1079-1089 (2012).
2. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6), 553-567 (2010).
3. Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360(22), 2289-2301 (2009).
4. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363(25), 2424-2433 (2010).
5. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12(9), 599-612 (2012).
6. Lbbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin. Oncol. 29(15), 1987-1996 (2011).
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 28(4), 562-569 (2010).
8. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999).
9. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000).
10. Eppert K, Takenaka K, Lechman ER et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17(9), 1086-1093 (2011).
11. Schoch C, Kohlmann A, Schnittger S et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc. Natl Acad. Sci. USA 99(15), 10008-10013 (2002).
12. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304(24), 2706-2715 (2010).
13. Christopeit M, Krger N, Haferlach T, Bacher U. Relapse assessment following allogeneic SCT in patients with MDS and AML. Ann. Hematol. 93(7), 1097-110 (2014).
14. Shearstone JR, Pop R, Bock C, Boyle P, Meissner A, Socolovsky M. Global DNA demethylation during mouse erythropoiesis in vivo. Science 334(6057), 799-802 (2011).
15. Bartholdy B, Christopeit M, Will B et al. HSC commitmentassociated epigenetic signature is prognostic in acute myeloid leukemia. J. Clin. Invest. 124(3), 1158-1167 (2014).
16. Agrawal S, Hofmann WK, Tidow N et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109(9), 3895-3905 (2007).
17. Jan M, Snyder TM, Corces-Zimmerman MR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4(149), 149ra118 (2012).
18. Schoofs T, Rohde C, Hebestreit K et al. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood 121(1), 178-187 (2013).
19. Hnisz D, Abraham BJ, Lee TI et al. Super-enhancers in the control of cell identity and disease. Cell 155(4), 934-947 (2013).
20. Figueroa ME, Skrabanek L, Li Y et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114(16), 3448-3458 (2009).
21. Bullinger L, Ehrich M, Dohner K et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 115(3), 636-642 (2010).
22. Figueroa ME, Lugthart S, Li Y et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1), 13-27 (2010).
23. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368(22), 2059-2074 (2013).
24. Alvarez S, Suela J, Valencia A et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 5(8):e12197 (2010).
25. Marcucci G, Yan P, Maharry K et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J. Clin. Oncol. 32(6), 548-556 (2014).
26. Deneberg S, Guardiola P, Lennartsson A et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 118(20), 5573-5582 (2011).
27. Cross M, Bach E, Tran T et al. Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. Onco. Targets Ther. 6, 741-748 (2013).
28. Shen L, Kantarjian H, Guo Y et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J. Clin. Oncol. 28(4), 605-613 (2010).
29. Akalin A, Garrett-Bakelman FE, Kormaksson M et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 8(6):e1002781 (2012).
30. Bhattacharyya S, Yu Y, Suzuki M et al. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Res. 41(16):e157 (2013).
31. Sun D, Luo M, Jeong M et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell 14(5), 673-688 (2014).
32. Krug U, Koschmieder A, Schwammbach D et al. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia-a randomised SAL pilot study. PLoS One 7(12):e52695 (2012).